Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsDNLI +5.63%33 Dividend Yield % is 0.00% as of Aug. 20, 2026. GuruFocus rates DNLI with a GF Score™ of 33/100. The stock has 6 warning signs investors should review. Among 150 Biotechnology companies, Denali Therapeutics ranks worse than 666666% on this metric.
As of today (2026-08-20), the Trailing Annual Dividend Yield of Denali Therapeutics is 0.00%.
The historical rank and industry rank for Denali Therapeutics's Dividend Yield % or its related term are showing as below:
DNLI's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.235 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Denali Therapeutics Dividend Yield % Related Terms
Denali Therapeutics Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DNLI vs RCUS, ALMS, ELVN: Dividend Yield % Comparison
For the Biotechnology subindustry, Denali Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Dividend Yield % falls into.
Denali Therapeutics (DNLI) has a Dividend Yield % of 0.00% as of Aug. 20, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Denali Therapeutics and its competitors. According to the industry distribution chart, Denali Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Denali Therapeutics' Dividend Yield % too high?
Denali Therapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Denali Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Denali Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Dividend Yield % compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #999999 out of 150 companies for Dividend Yield %. This places Denali Therapeutics in the lower half of its industry. The industry median Dividend Yield % is 1.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.24, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (DNLI) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Denali Therapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Denali Therapeutics (DNLI), the current Dividend Yield % is 0.00% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score
Get the complete analysis for DNLI
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNLI has been successfully added to your 
